Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 32Colonic Neoplasms 8Rectal Neoplasms 7Neoplasm Metastasis 5Stomach Neoplasms 3Pancreatic Neoplasms 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Neutropenia 2Bile Duct Neoplasms 2Adenocarcinoma 2mCRC 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasms 1Nasopharyngeal Carcinoma 1Microsatellite-stable Colorectal Cancer 1Lung Neoplasms 1High-grade Extra Pulmonary Neuroendocrine Cancer 1Gastric Cancer Adenocarcinoma Metastatic 1First-line Treatment 1Esophageal Squamous Cell Carcinoma 1EFS 1Dihydropyrimidine Dehydrogenase Deficiency 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × EFS × trifluridine tipiracil drug combination × Clear all
NCT07090031 2025-07-29

Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer

Qingdao Central Hospital

Phase 2 Active not recruiting
49 enrolled

EFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡